reports
89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity...
89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASH Webinar to feature a presentation from expert hepatologist Arun Sanyal, M.D., on Thursday, May 16th at 10am ET SAN FRANCISCO, May 02, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that it will host a key opinion leader (KOL) event of pegozafermin’s opportunity in advanced metabolic dysfunction-associated ste...
CPS Announces $319.9 Million Senior Subordinate Asset-Backed Securitiz...
CPS Announces $319.9 Million Senior Subordinate Asset-Backed Securitization LAS VEGAS, Nevada, April 23, 2024 (GLOBE NEWSWIRE) -- Consumer Portfolio Services, Inc. (Nasdaq: CPSS) (“CPS” or the “Company”) announced the closing of its second term securitization in 2024 on Tuesday April 23, 2024. The transaction is CPS's 51st senior subordinate securitization since the beginning of 2011 and the 34th consecutive securitization to receive a triple “A” rating from at least two rating agencies on the senior class of notes. In the transaction, qualified institutional buyers purchased $319.9 mill...
89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of...
89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors SAN FRANCISCO, April 17, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the appointment of Martin Babler to its Board of Directors, effective April 13, 2024. Mr. Babler, a highly successful executive who brings valuable industry experience to 89bio, currently serves as President, Chief Executive Officer and Chairman o...
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 138,550 shares of the Company’s common stock to eight new employees (the “Inducement...
Consumer Portfolio Services Appoints Gateway to Lead Expanded Investor...
Consumer Portfolio Services Appoints Gateway to Lead Expanded Investor Relations Program LAS VEGAS, NV, April 03, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CPSS) (“CPS” or the “Company”), an independent specialty finance technology company that provides indirect automobile financing to individuals with past credit problems, low incomes or limited credit histories, has appointed , a leading strategic financial communications and capital markets advisory firm, to manage its expanded investor relations program initiatives, including providing corporate messaging and other consulting services to the...
CPS Announces Renewal of $200 Million Credit Facility
CPS Announces Renewal of $200 Million Credit Facility LAS VEGAS, Nevada, April 01, 2024 (GLOBE NEWSWIRE) -- Consumer Portfolio Services, Inc. (Nasdaq: CPSS) (“CPS” or the “Company”) today announced that on March 29, 2024, it renewed its two-year revolving credit agreement with Ares Agent Services, L.P. Loans under the renewed credit agreement will be secured by automobile receivables that CPS now holds, will originate directly, or will purchase from dealers in the future. CPS may borrow on a revolving basis through March 31, 2026, after which CPS will have the option to repay the outstan...
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of M...
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis –PRIME status is supported by positive data from the Phase 2b ENLIVEN trial of pegozafermin– –Phase 3 ENLIGHTEN-Fibrosis trial in non-cirrhotic MASH (fibrosis stage F2-F3) patients is enrolling and ENLIGHTEN-Cirrhosis in MASH patients with compensated cirrhosis (F4) is planned to initiate in the second quarter of 2024– SAN FRANCISCO, March 27, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharm...
CPS Announces $50.0 Million Securitization of Residual Interests
CPS Announces $50.0 Million Securitization of Residual Interests LAS VEGAS, Nevada, March 22, 2024 (GLOBE NEWSWIRE) -- Consumer Portfolio Services, Inc. (Nasdaq: CPSS) (“CPS” or the “Company”) today announced the closing of a $50.0 million securitization of residual interests from previously issued securitizations. In the transaction, a qualified institutional buyer purchased $50.0 million of asset-backed notes secured by an 80% interest in a CPS affiliate that owns the residual interests in five CPS securitizations issued from January 2022 through January 2023. Collateral for the note...
CPS Announces Fourth Quarter and Full Year 2023 Earnings
CPS Announces Fourth Quarter and Full Year 2023 Earnings Pretax income of $9.8 million for the fourth quarter and $61.1 million for 2023Revenues of $92.0 million for the fourth quarter and $352.0 million for 2023Net income of $45.3 million, or $1.80 per diluted share for 2023New contract purchases of $1.358 billion for the full year 2023Largest managed portfolio balance in company history, $3.2 billion LAS VEGAS, NV, March 15, 2024 (GLOBE NEWSWIRE) -- Consumer Portfolio Services, Inc. (Nasdaq: CPSS) (“CPS” or the “Company”) today announced earnings of $7.2 million, or $0.29 per dil...
CPS to Host Conference Call on Fourth Quarter 2023 Earnings
CPS to Host Conference Call on Fourth Quarter 2023 Earnings LAS VEGAS, Nevada, March 14, 2024 (GLOBE NEWSWIRE) -- Consumer Portfolio Services, Inc. (Nasdaq: CPSS) (“CPS” or the “Company”) today announced that it will hold a conference call on Monday, March 18, 2024 at 1:00 p.m. ET to discuss its fourth quarter 2023 operating results. Those wishing to participate can pre-register for the conference call at the following link . Registered participants will receive an email containing conference call details for dial-in options. To avoid delays, we encourage participants to dial into the co...
89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in No...
89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis —Co-primary endpoints in ENLIGHTEN-Fibrosis assessed at week 52 will potentially support accelerated approval in non-cirrhotic MASH (fibrosis stage F2-F3) patients— —ENLIGHTEN-Cirrhosis, the second trial in the program, is planned to evaluate patients with compensated cirrhosis (F4) and is expected to initiate in the second quarter of 2024— SAN FRANCISCO, March 12, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-...
- Jonathan Moreland
SEDG SOLAREDGE TECHNOLOGIES INC.
PRGO PERRIGO CO. PLC
GOGO GOGO INC.
D DOMINION ENERGY INC
CTRN CITI TRENDS INC.
CLFD CLEARFIELD INC.
CFFN CAPITOL FEDERAL FINANCIAL INC.
HWBK HAWTHORN BANCSHARES
FMC FMC CORPORATION
RIGN TRANSOCEAN LTD.
SPWR SUNPOWER CORPORATION
AFT APOLLO SENIOR FLOATING RATE FUND INC.
NQP NUVEEN PENNSYLVANIA INVESTMENT QUALITY MUNICIPAL FUND INC.
NXJ NUVEEN NEW JERSEY DIVIDEND ADVANTAGE MUNICIPAL FUND
HCC WARRIOR MET COAL INC.
RBB RBB BANCORP
AXR AMREP
FSK FS KKR CAPITAL CORP
KSM DWS STRATEGIC MUNICIPAL INCOME TRUST
ETNB 89BIO
PCB PACIFIC CITY FINANCIAL CORP
BSBK BOGOTA FINANCIAL CORP.
CZR CAESARS ENTERTAINMENT INC
WSC WILLSCOT MOBILE MINI HOLDINGS CORP
THRY THRYV HOLDINGS
ABCL ABCELLERA BIOLOGICS
LSEA LANDSEA HOMES CORP (A)
LUMN LUMEN TECHNOLOGIES INC.
SLRC SOLAR CAPITAL LTD.
ONDS ONDAS HOLDINGS
PFX PHENIXFIN CORP
WES WESTERN MIDSTREAM PARTNERS LP
ABSI ABSCI CORP
VPV INVESCO PA VALUE MUNI INC TST
GATO SUNSHINE SILVER MINING AND REFINING CORP
LSXMA LIBERTY SIRIUSXM GROUP
LSXMK BURKE HERBERT FINANCIAL SERVICES CORP
BHRB ALLSCRIPTS-MISYS HEALTHCARE SOLUTIONS
MDRX INC.
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) SAN FRANCISCO, March 08, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 10,800 shares of the Company’s common stock to a new employee (the “Inducement Grant”...
- Jonathan Moreland
NQP NUVEEN PENNSYLVANIA INVESTMENT QUALITY MUNICIPAL FUND INC.
NXJ NUVEEN NEW JERSEY DIVIDEND ADVANTAGE MUNICIPAL FUND
AXR AMREP
ZM ZOOM VIDEO COMMUNICATIONS
KSM INC.
ETNB DWS STRATEGIC MUNICIPAL INCOME TRUST
ADPT 89BIO
SLRC ADAPTIVE BIOTECHNOLOGIES
WES SOLAR CAPITAL LTD.
VPV WESTERN MIDSTREAM PARTNERS LP
LSXMA INVESCO PA VALUE MUNI INC TST
LIBERTY SIRIUSXM GROUP
89bio to Participate in the Leerink Partners Global Biopharma Conferen...
89bio to Participate in the Leerink Partners Global Biopharma Conference SAN FRANCISCO, March 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on Tuesday, March 12, 2024 at 1:40 PM EST and participate in one-on-one investor meetings. The webcast of the fireside chat will be acce...
89bio Reports Fourth Quarter and Full Year 2023 Financial Results and ...
89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates – Plan to initiate the Phase 3 ENLIGHTEN NASH program for non-cirrhotic (F2-F3) and cirrhotic (F4) patients in the first and second quarters of 2024, respectively – – Long-term data from Phase 2b ENLIVEN trial demonstrated sustained benefits of pegozafermin at week 48 in patients with advanced NASH, which was consistent across patient sub-groups – – Data from Phase 2b ENLIVEN trial in patients with cirrhotic NASH were featured in an oral presentation during American Association for the...
- Jay Kornreich
- Richard Anderson
89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sc...
89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference SAN FRANCISCO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024 at 1:20 PM EST and participate in one-on-one investor meetings. The webcast of the presentation will...
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN FRANCISCO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 28,400 shares of the Company’s common stock to two new employees (the “Inducement Gra...
- Jonathan Moreland
CWBC_x COMMUNITY WEST BANKSHARES
TLYS TILLYS
STAA STAAR SURGICAL CO.
PBF PBF ENERGY INC. CLASS A
OPK OPKO HEALTH INC.
LPSN LIVEPERSON INC.
FDX FEDEX CORPORATION
CPRX CATALYST PHARMACEUTICALS
CODI COMPASS DIVERSIFIED HOLDINGS
ASA ASA
PESI PERMA-FIX ENVIRONMENTAL SERVICES INC.
ADC AGREE REALTY CORPORATION
FIZZ NATIONAL BEVERAGE CORP.
FBK FB FINANCIAL CORPORATION
PKTX PROTOKINETIX INC
JGH NUVEEN GLB HG
CMXC CELL MEDX
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
CSBB C S B BANCORP OHIO
BWB BRIDGEWATER BANCSHARES
ZIVO ZIVO BIOSCIENCE
VRCA INC.
LOVE VERRICA PHARMACEUTICALS
TLRY LOVESAC
FBIO TILRAY
ACET FABIEN CORP
GRPN ADICET BIO INC
HPK GROUPON INC.
ATHA HIGHPEAK ENERGY INC (A)
VRDN ATHIRA PHARMA
AGL VIRIDIAN THERAPEUTICS INC
MPA AGILON HEALTH
SLDB INC.
BPRN BLACKROCK MUNIYIELD PENNSYLVANIA FD
MBRX SOLID BIOSCIENCES INC
LSXMA BANK OF PRINCETON
MOLECULIN BIOTECH INC
LIBERTY SIRIUSXM GROUP
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.